Dominik Escher

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then.

NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland.

NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland.

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then.

NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.